News

Cohen & Steers Reports on Asset Management Trends in 2025

Cohen & Steers Reports on Asset Management Trends in 2025

Understanding Cohen & Steers' Asset Management Insights

Cohen & Steers, Inc. (NYSE: CNS) has recently shared its preliminary assets under management (AUM), revealing significant trends for July 2025. The AUM was reported at $88.6 billion as of July 31, indicating a decrease from one month prior. Specifically, the firm's assets fell by $353 million from $88.9 billion on June 30, highlighting the volatile nature of the market.

The Factors Behind the Changes in AUM

This decline in AUM can be attributed to multiple elements. Notably, market depreciation played a significant role, accounting for approximately $410 million in losses. Additionally, distributions, totaling $152 million, further contributed to the decrease. However, it should be noted that the firm did experience a positive aspect during this period, with net inflows reaching $209 million, suggesting that client investments are still actively flowing into the firm despite market fluctuations.

A Breakdown of Performance by Investment Vehicle

To gain deeper insight into these trends, it is important to consider the performance across different investment vehicles. Cohen & Steers classifies its assets by performance metrics, which include institutional accounts, open-end funds, and closed-end funds. Each category has seen unique trends that signal where investors are placing their confidence.

The State of Institutional Accounts

Institutional accounts have played a pivotal role in the overall AUM landscape. The total AUM in this category was recorded at $34.386 billion, reflecting a net decrease of $86 million in July. This performance underscores the challenges that institutional investors face in the current market. Examining specific segments, advisory accounts remained relatively stable, although they also faced slight withdrawals. Regulatory compliance and strategic asset allocation continue to be a focus of institutional investors as they navigate these shifts.

Exploring Open-End and Closed-End Fund Performance

Turning our attention to open-end and closed-end funds reveals contrasting outcomes. Open-end funds showed resilience, as total AUM reached $43 billion, with net inflows of $294 million. Conversely, closed-end funds encountered a decline in assets, ultimately totaling $11.580 billion. This disparity highlights differing investor sentiment toward fund structures and indicates a preference for liquidity in uncertain market conditions.

Future Outlook for Cohen & Steers

As Cohen & Steers moves forward, there remains a cautious optimism. With $88.6 billion in AUM, the firm is actively adapting to market dynamics, focusing on enhancing its offerings in real assets and alternative income. Analysts are closely watching the strategies deployed by the firm to bolster its growth, particularly in light of recent outflows and turbulent market conditions. Cohen & Steers is likely to continue promoting its expertise in real estate, preferred securities, and infrastructure investments in pursuit of recovery and growth.

Conclusion

The recent asset management report from Cohen & Steers reflects a complex landscape characterized by challenges and opportunities. As the firm navigates current market realities, the adeptness shown in managing both net inflows and AUM will be crucial to maintaining its competitive edge.

Frequently Asked Questions

What was Cohen & Steers' AUM for July 2025?

The AUM reported was $88.6 billion, which indicates a decrease from the previous month.

What were the primary factors contributing to the decrease in AUM?

The decrease was largely due to market depreciation and distributions, offset slightly by net inflows.

What do net inflows indicate about investor confidence?

Net inflows suggest ongoing investor confidence in the firm's management strategies despite market volatility.

How do institutional accounts impact Cohen & Steers' overall performance?

Institutional accounts represent a significant portion of AUM, showing both stability and challenges during uncertain market conditions.

What is the outlook for Cohen & Steers moving forward?

The firm is expected to adapt its strategies in response to market changes, focusing on real assets and alternative income.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 627

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Gildan's Crisis: Investors Face Losses Amid Lawsuit

Updated Category News Views 245

Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 311

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
LG's ASIL D Certification: A Game Changer in Autos

Updated Category News Views 150

Why LG's ASIL D Certification Matters There ain't much in the tangled mess of automotive innovations these days that'll make a seasoned investor raise an eyebrow, but here comes LG Electronics grabbing the ASIL D certification like it's a badge of market honor. The ISO 26262 ASIL D is no walk in the park, folks—it's the top rung on the safety ladder, something that's...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 364

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 105

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
GlycoNex Eyes Japanese Market with Denosumab Biosimilar

Updated Category News Views 108

A Strategic Step into the Japanese Market Alright folks, there's a new kid aiming to shake things up in the biotech neighborhood, and it's GlycoNex with its denosumab biosimilar, SPD8. These guys just tossed their hat in the ring with a regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency (PMDA). If the cosmic forces align, they might snag an...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 354

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Fibocom Unveils U6G Solutions Advancing Global 5G Tech

Updated Category News Views 35

Breaking Barriers with U6G-Capable Technology Sneaking into the industry's spotlight at MWC Doha 2026, Fibocom flaunts a robust lineup of next-gen 5G solutions. It's as if they're shuffling every card they’ve got to win over the broadband world. With breakthroughs like the FG390, FG370, and FG670 modules, alongside PCBA-level innovations, Fibocom is not just throwing...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 364

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

DESRI Completes Major Financing for Texas Solar Projects

Updated Category News Views 324

DESRI Completes Major Financing for Texas Solar Projects Today, DESRI proudly announced that it has closed a significant preferred equity financing of $129 million aimed at a 250-megawatt (MWac) solar development portfolio. This portfolio consists of two innovative solar projects located in West Texas, an area ripe for renewable energy enhancement. Meeting Industrial...

Continue Reading
Colossal Foundation Invests $500,000 in Condor Restoration Efforts

Updated Category News Views 76

Colossal Foundation Invests in Wildlife Recovery The Colossal Foundation has made a significant commitment of $500,000 towards restoring the California condor to its ancestral skies. This incredible movement represents a decade-long partnership with the Nez Perce Tribe, focusing on the recovery and reintroduction of North America’s largest land bird. For more than a...

Continue Reading
Revolutionary Self-Healing Film: The Future of Waterproofing

Updated Category News Views 108

Revolutionary Waterproofing Solutions by Charter Next Generation Charter Next Generation (CNG) recently unveiled its groundbreaking Nail Sealable film technology, designed to transform waterproofing in the construction industry. This pioneering self-healing film stands out with its exceptional moisture resistance and remarkable durability, making it a game changer for...

Continue Reading
Sonnet BioTherapeutics Provides Positive Safety Insights on SON-1010

Updated Category News Views 273

Exciting Safety Data from Sonnet BioTherapeutics’ SON-1010 Trial Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has unveiled impressive topline safety data following a successful dose escalation of SON-1010 in the Phase 1 SB101 clinical trial. The study focused on the administration of SON-1010 to patients suffering from advanced solid tumors, marking a significant...

Continue Reading
Key Legal Information for Symbotic Inc. Shareholders

Updated Category News Views 73

Important Information for Symbotic Inc. Investors Recent developments surrounding Symbotic Inc. have captured the attention of investors globally. Investors who are shareholders of Symbotic Inc. (NASDAQ: SYM) may need to be aware of significant deadlines regarding a recent securities class action lawsuit. Overview of the Lawsuit Investors are reminded that they may have...

Continue Reading